Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
Identifieur interne : 004936 ( Ncbi/Merge ); précédent : 004935; suivant : 004937Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
Auteurs : M F Gordon [États-Unis] ; R. Diaz-Olivo ; A L Hunt ; S. FahnSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (therapeutic use), Administration, Oral, Adult, Aged, Basal Ganglia (drug effects), Basal Ganglia (physiopathology), Blood-Brain Barrier (drug effects), Double-Blind Method, Female, Glycine (therapeutic use), Humans, Male, Middle Aged, Movement Disorders (classification), Movement Disorders (drug therapy), Movement Disorders (physiopathology), Synaptic Transmission (drug effects), Videotape Recording.
- MESH :
- chemical , administration & dosage : Acetamides.
- chemical , therapeutic use : Acetamides, Glycine.
- classification : Movement Disorders.
- drug effects : Basal Ganglia, Blood-Brain Barrier, Synaptic Transmission.
- drug therapy : Movement Disorders.
- physiopathology : Basal Ganglia, Movement Disorders.
- Administration, Oral, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Videotape Recording.
Abstract
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.
DOI: 10.1002/mds.870080412
PubMed: 8232358
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004B83
- to stream PubMed, to step Curation: 004B83
- to stream PubMed, to step Checkpoint: 004B85
Links to Exploration step
pubmed:8232358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</title>
<author><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology, Columbia-Presbyterian Medical Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name>
</author>
<author><name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name>
</author>
<author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1993">1993</date>
<idno type="RBID">pubmed:8232358</idno>
<idno type="pmid">8232358</idno>
<idno type="doi">10.1002/mds.870080412</idno>
<idno type="wicri:Area/PubMed/Corpus">004B83</idno>
<idno type="wicri:Area/PubMed/Curation">004B83</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004B85</idno>
<idno type="wicri:Area/Ncbi/Merge">004936</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</title>
<author><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology, Columbia-Presbyterian Medical Center, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name>
</author>
<author><name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name>
</author>
<author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1993" type="published">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (therapeutic use)</term>
<term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Basal Ganglia (drug effects)</term>
<term>Basal Ganglia (physiopathology)</term>
<term>Blood-Brain Barrier (drug effects)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Glycine (therapeutic use)</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Movement Disorders (classification)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (physiopathology)</term>
<term>Synaptic Transmission (drug effects)</term>
<term>Videotape Recording</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Glycine</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term>
<term>Blood-Brain Barrier</term>
<term>Synaptic Transmission</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term>
<term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Videotape Recording</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8232358</PMID>
<DateCreated><Year>1993</Year>
<Month>12</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>1993</Year>
<Month>12</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>8</Volume>
<Issue>4</Issue>
<PubDate><Year>1993</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</ArticleTitle>
<Pagination><MedlinePgn>484-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName>
<ForeName>M F</ForeName>
<Initials>MF</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Diaz-Olivo</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hunt</LastName>
<ForeName>A L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fahn</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0HXT24RECU</RegistryNumber>
<NameOfSubstance UI="C039332">milacemide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>TE7660XO1C</RegistryNumber>
<NameOfSubstance UI="D005998">Glycine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000081">Acetamides</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005998">Glycine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009435">Synaptic Transmission</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D014743">Videotape Recording</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year>
<Month>10</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1993</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1993</Year>
<Month>10</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">8232358</ArticleId>
<ArticleId IdType="doi">10.1002/mds.870080412</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name>
<name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name>
<name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004936 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004936 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:8232358 |texte= Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8232358" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |